Martin Javier San

CIK: 0001794629

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (28.6%)

Position reduction

Option Exercises (M)4 (28.6%)

Derivative conversions

Awards (A)6 (42.9%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

LONA

LeonaBio, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (14 total)

LONA
LeonaBio, Inc.
Apr 9, 2026
Award(A)
Stock Option (Right to Buy)
Direct
350K shares-
LONA
LeonaBio, Inc.
Mar 4, 2026
Sale(S)
Direct
1.7K shares at avg. $5.37$9K
LONA
LeonaBio, Inc.
Mar 3, 2026
Exercise(M)
Direct
7.4K shares-
ATHA
Athira Pharma, Inc.
Jan 2, 2026
Sale(S)
Direct
1.6K shares at avg. $6.88$11K
ATHA
Athira Pharma, Inc.
Dec 31, 2025
Exercise(M)
Direct
4.7K shares-
ATHA
Athira Pharma, Inc.
Dec 24, 2025
Award(A)
Stock Option (Right to Buy)
Direct
44.5K shares-
ATHA
Athira Pharma, Inc.
Jul 1, 2025
Sale(S)
Direct
10.8K shares at avg. $0.29$3K
ATHA
Athira Pharma, Inc.
Jun 30, 2025
Exercise(M)
Direct
46.7K shares-
ATHA
Athira Pharma, Inc.
Mar 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
111.3K shares-
ATHA
Athira Pharma, Inc.
Mar 3, 2025
Award(A)
Restricted Stock Units
Direct
74.2K shares-
ATHA
Athira Pharma, Inc.
Jan 2, 2025
Sale(S)
Direct
10.8K shares at avg. $0.56$6K
ATHA
Athira Pharma, Inc.
Dec 31, 2024
Exercise(M)
Direct
46.7K shares-
ATHA
Athira Pharma, Inc.
Oct 1, 2024
Award(A)
Restricted Stock Units
Direct
140K shares-
ATHA
Athira Pharma, Inc.
Oct 1, 2024
Award(A)
Stock Option (Right to Buy)
Direct
140K shares-

		Type	Shares	Price		Ownership
Apr 9, 2026	LONA LeonaBio, Inc.	Award(A) Stock Option (Right to Buy)	350,000	-	-	Direct
Mar 4, 2026	LONA LeonaBio, Inc.	Sale(S)	1,720	$5.37	$9,236	Direct
Mar 3, 2026	LONA LeonaBio, Inc.	Exercise(M)	7,418	-	$0	Direct
Jan 2, 2026	ATHA Athira Pharma, Inc.	Sale(S)	1,644	$6.88	$11,311	Direct
Dec 31, 2025	ATHA Athira Pharma, Inc.	Exercise(M)	4,667	-	$0	Direct
Dec 24, 2025	ATHA Athira Pharma, Inc.	Award(A) Stock Option (Right to Buy)	44,508	-	-	Direct
Jul 1, 2025	ATHA Athira Pharma, Inc.	Sale(S)	10,842	$0.29	$3,182	Direct
Jun 30, 2025	ATHA Athira Pharma, Inc.	Exercise(M)	46,666	-	-	Direct
Mar 3, 2025	ATHA Athira Pharma, Inc.	Award(A) Stock Option (Right to Buy)	111,270	-	-	Direct
Mar 3, 2025	ATHA Athira Pharma, Inc.	Award(A) Restricted Stock Units	74,180	-	-	Direct
Jan 2, 2025	ATHA Athira Pharma, Inc.	Sale(S)	10,826	$0.56	$6,083	Direct
Dec 31, 2024	ATHA Athira Pharma, Inc.	Exercise(M)	46,667	-	$0	Direct
Oct 1, 2024	ATHA Athira Pharma, Inc.	Award(A) Restricted Stock Units	140,000	-	-	Direct
Oct 1, 2024	ATHA Athira Pharma, Inc.	Award(A) Stock Option (Right to Buy)	140,000	-	-	Direct

1-14 of 14 transactions

About San Martin Javier

San Martin Javier (SEC CIK 0001794629) files insider reports with the SEC as CHIEF MEDICAL OFFICER of LeonaBio, Inc. (LONA).

Signal8 holds 8 ownership filings by San Martin Javier, all Form 4s, filed between Oct 3, 2024 and Apr 13, 2026. Those filings report 14 transactions, from Oct 1, 2024 to Apr 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on San Martin Javier's filings is in BOTHELL, WA.

Recent filings by San Martin Javier

Apr 9, 2026: Grant or award of LONA derivative securities (Form 4, code A).
Mar 4, 2026: Open-market sale of LONA shares (Form 4, code S).
Mar 3, 2026: Option exercise of LONA shares (Form 4, code M).
Jan 2, 2026: Open-market sale of ATHA shares (Form 4, code S).
Dec 31, 2025: Option exercise of ATHA shares (Form 4, code M).

Other insiders filing for LeonaBio, Inc. (LONA)

How to read Form 4 transaction codes